ANGPTL3 Inhibitors: Uses, Common Brands, and Safety Info
The article provides information on ANGPTL3 inhibitors, a drug class used to lower levels of bad cholesterol and triglycerides in individuals with familial hypercholesterolemia. It discusses their uses, common brands, and safety considerations.
Uses
The drug class ANGPTL3 inhibitors is a group of medications that help lower levels of a protein called angiopoietin-like 3 (ANGPTL3) in the body. This protein regulates lipid metabolism, or the breakdown and storage of fats in the body. By inhibiting ANGPTL3, these medications can help lower levels of low-density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, and triglycerides. ANGPTL3 inhibitors are primarily used to treat individuals with familial hypercholesterolemia, a genetic disorder characterized by abnormally high levels of cholesterol and triglycerides.
Common Brands
Some common brands of ANGPTL3 inhibitors include evinacumab, which is marketed under the brand name Evkeeza. Evinacumab is an injectable medication that is used in combination with other lipid-lowering treatments to treat familial hypercholesterolemia.
Safety
The use of ANGPTL3 inhibitors may be associated with certain safety considerations. As with most medications, individuals who are allergic to any components of ANGPTL3 inhibitors should avoid their use. Additionally, individuals with liver disease may need dose adjustments or close monitoring while taking these medications.
Common side effects of ANGPTL3 inhibitors may include injection site reactions, flu-like symptoms, and gastrointestinal disturbances. These side effects are generally mild and temporary, but it is important to consult a healthcare professional if they persist or worsen.
It is crucial to discuss all current medications and medical conditions with a healthcare provider before starting treatment with ANGPTL3 inhibitors. They may interact with certain medications, including those used to treat high cholesterol or triglycerides, and may not be suitable in some medical conditions.
Overall, ANGPTL3 inhibitors have shown significant benefits in reducing "bad" cholesterol and triglyceride levels, making them a valuable addition to the treatment armamentarium for individuals with familial hypercholesterolemia.